Pharmaceuticals, Biotechnology and Life Sciences
Patients with certain plaque psoriasis treated with 300mg of Cosentyx for only four weeks reported in a questionnaire improvements in life quality, novartis said Monday.
U.S. Food and Drug Administration (FDA) approved AbbVie’s Imruvica (ibrutinib) combined rituximab (Rituxan) for treating adult patients with Waldenström’s macroglobulinemia (WM).
Destiny Pharma’s XF-73 nasal gel formulation has been classified non-irritant, in the second Phase 1 study, which confirms the good safety profile.
Theravance Biopharma has started dosing patients with symptomatic neurogenic orthostatic hypotension (nOH) to test its investigational neropinephrine reuptake inhibitor ampreloxetine (TD-9855), in a registrational Phase 3 clinical trial
Amgen’s Repatha will now be used as the first PCSK9 inhibitor in China for adults with established atherosclerotic cardiovascular disease (ASCVD) to reduce the risk of myocardial infarction, stroke and coronary revascularization.
Philogen S.p.A., a privately-owned biotechnology company, today announced through its wholly-owned Swiss subsidiary, Philochem AG, a collaboration agreement with Janssen Biotech to discover new small molecule-based therapeutics utilizing Philochem’s novel lead-generation technologies.
The Wasdell Group (Wasdell), a leading outsourcing partner for companies in the pharmaceutical and clinical trials industries, has been granted its Health Products Regulatory Authority (HPRA) licence for its new EU headquarters in Dundalk, Ireland.
In line with KRAIBURG TPE’s 2019 strategy to increase its focus on medical applications and pharmaceutical packaging, the company recently collaborated with Eastman to develop a range of innovative high-purity TPEs. In close cooperation with Eastman, KRAIBURG TPE has developed a range of THERMOLAST® M thermoplastic elastomers (TPEs) with the capability to adhere directly to specialized polymers used in medical applications, including Eastman’s Tritan™ copolyester, PP, ABS, ABS/PC, and PET.
Trovagene has expanded the use of Onvansertib to enable it for combination therapies with anti-androgen drugs, like Zytiga, Xtandi and Erledea to treat castrate-resistant prostate cancer.
Actinium Pharmaceuticals has appointed Cynthia Pussinen as Executive Vice President, Technical Operations and Supply Chain, who will also serve as a member of Actinium’s executive leadership team.